menu
    • menu
    [{"orgOrder":0,"company":"Medicilon","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicilon & Hengrui Pharma Deepen Collaboration on ADCs, Small Nucleic Acids, & CGT Drugs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Medicilon","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicilon \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":null,"companyTruncated":"Medicilon .."}]

    Find Clinical Drug Pipeline Developments & Deals by Medicilon

    Menu

    Medicilon

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medicilon

                            China arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Medicilon

                            China arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Partner/Sponsor/Collaborator : Jiangsu Hengrui Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Medicilon & Hengrui Pharma Deepen Collaboration on ADCs, Small Nucleic Acids, & CGT Drugs

                            Details : Medicilon & Hengrui will collaborate to focus on the preclinical evaluation of new drug modalities such as ADCs, small molecules, etc & to advance the innovation to compete on an international level.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 31, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Partner/Sponsor/Collaborator : Jiangsu Hengrui Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth